In addition, incretin enthusiasts had suffered a serious disappointment, when it was observed, at about the same time, that GIP although being potently insulinotropic in healthy individuals was ineffective in patients with type 2 diabetes ( not including secretin) also was a potent inhibitor of glucagon secretion ( Inspired by the similarity of GLP-1 with glucagon and oxyntomodulin, it was relevant to look at other glucagon-like gastro-intestinal actions of GLP-1, and via extensive human studies it was soon established that GLP-1 was a physiological and powerful inhibitor of gastrointestinal secretion (both gastric and pancreatic) and motility ( In spite of the disappointment with GIP in T2DM, it was time to see whether the new incretin would have any effects in T2DM patients
DOI: 10.1038/srep31788 [Google Scholar] Wu YC, Wang WT, Lee SS, Kuo YR, Wang YC, Yen SJ, et al
Never use the same exact spot on consecutive days
May your drops stay potent, your hold times stay long, and your results stay consistent.
Major advances in the understanding of the structure of class B GPCRs have recently been made, including for the GLP-1R 63,64